A phase 2 study of ridaforolimus and dalotuzumab in estrogen receptor positive breast cancer
José Baselga(Novartis (Switzerland)), Hope S. Rugo, Antoinette R. Tan(Wake Forest University), Peter Vuylsteke(Champalimaud Foundation), Christine K. Gause(Merck & Co., Inc., Rahway, NJ, USA (United States)), B. Moy, Lamar Eaton(Merck & Co., Inc., Rahway, NJ, USA (United States)), David J. Mauro(Moffitt Cancer Center), Ellie Im(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kathryn J. Ruddy, Javier Cortes, Marianne; id_orcid 0000-0002-5965-969X Ewertz, Tufia Haddad, Kumudu Prathiraja, Ahmad Awada, Eva M. Ciruelos, Serafin M. Morales, Joanne L. Blum, Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States))
University of Southern Denmark Research Portal (University of Southern Denmark)
January 1, 2013
Cited by 0
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k